Creating a new non-hormonal contraceptive using anti-sperm antibodies
Official title: Development of an ultrapotent anti-sperm antibody construct for non-hormonal contraception
Funded at Mucommune, LLC · NIH-11063679 · Data updated 2026-11-12
This study is exploring a new, easy-to-use birth control method that involves a ring you place inside your vagina, which releases a special antibody to help stop sperm from reaching an egg, giving you more control without the need for daily pills or timing.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mucommune, LLC NIH-funded |
| Lab location | 1 site (Morrisville, UNITED STATES) |
| Project start | March 25, 2025 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $380,692 |
| NIH project number | 1R61HD117428-01 |
| Project ID | NIH-11063679 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are women seeking non-hormonal contraceptive methods who may have concerns about hormonal side effects.
✕Less likely to help
Patients who are not interested in contraceptive methods or those who prefer hormonal options may not benefit from this research.
What this research studies
This research aims to develop a non-hormonal contraceptive method that utilizes an intravaginal ring to release an anti-sperm antibody. This antibody works by agglutinating and trapping sperm in mucus, preventing them from reaching the egg. The approach is designed to provide a user-controlled contraceptive option that does not require daily dosing or timing with intercourse. The research builds on previous studies that demonstrated the effectiveness of anti-sperm antibodies in reducing sperm motility.
Why it matters
Potential benefit: If successful, this research could provide women with a safe and effective non-hormonal contraceptive option.
How similar studies have gone: Previous research has shown success with anti-sperm antibodies in reducing sperm motility, indicating potential for this novel approach.
Where this research is happening
-
Mucommune, LLC
Morrisville, United States Active
Researchers
- Principal investigator: Kushiro, Keiichiro — Mucommune, LLC
- Study coordinator: Kushiro, Keiichiro
Related research
Other NIH-funded projects on the same topics.
-
Mobile health support to boost PrEP and contraception use among young women in Zambia
A mobile health program helps female university students in Zambia learn about and access HIV prevention and contraception.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Long‑lasting antibody vaginal ring for non‑hormonal birth control
Testing a vaginal ring that slowly releases an antibody to trap sperm and prevent pregnancy for people seeking non‑hormonal contraception.
-
A woman-controlled, nonhormonal on-demand contraceptive device
This project is creating a woman-controlled vaginal device that releases a fabric-like polymer which thickens on contact with semen to help prevent pregnancy.
-
Vaginal ring releasing non-hormonal antibody contraception for month-long use
A monthly vaginal ring delivers a non-hormonal antibody-based contraceptive, offering a convenient, user-controlled option for women who want to avoid daily dosing or invasive procedures.
-
On-demand non-hormonal vaginal contraception with a fast-dissolving antibody tablet
A new on-demand vaginal tablet dissolves quickly to release a monoclonal antibody for non-hormonal contraception.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.